

References

I-28

1. Blair H A, Deeks E D. Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases. *BioDrugs*. 2016;469-480.
2. Clinical Pharmacology Compendia™. 2023. Tampa FL: Gold Standard, Inc. Infliximab.
3. Remicade® (Infliximab), for injection, for intravenous use [package insert]. Janssen Biotech, Inc. Horsham, PA. revised 10/2021.
4. Inflectra® (infliximab-dyyb), for injection, for intravenous use [package insert]. Lake Forest, IL. Jansen Pfizer Company. 04/2023.
5. Renflexis (infliximab-abda), for injection, for intravenous use [package insert]. Kenilworth, NJ. Merck Sharp & Dohme Corp. 01/2022.
6. ASHP Guidelines on Home Infusion Pharmacy Services, 2013.
7. Lichtenstein G, Loftus E, Isaacs K, et al. ACG Clinical Guideline: Management of Crohn's Disease in Adults. *Am J Gastroenterol*. 2018;113:481-517.
8. Menter A, Gottlieb A, Feldman S, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. *J Am Acad Dermatol*. 2018;58(5):826-850.
9. Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American gastroenterological association IBD parenthood project working group. *Gastroenterology*. 2019;156(5):1508-1524.
10. Menter A, Strober B, Kaplan D, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol*. 2019;80:1029-1072.
11. Singh J, Saag K, Bridges Jr S, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Care Res*. 2015;68(1):1-25.
12. Rubin D, Snanthakrishnan A, Siegel C, et al. ACG clinical guideline: ulcerative colitis in adults. *Am J Gastroenterol*. 2019;114:384-413
13. Avsola™ (infliximab-axxq), for injection, for intravenous use [package insert]. Amgen Inc. Thousand Oaks, CA. 2019. Revised 09/2021.
14. Tajiri H, Arai K, Kagimoto S, et al. Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan. *BMC Pediatrics*. 2019;19:351.
15. Goll G, Jorgensen K, Sexton J, et al. Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial. *J Intern Med*. 2019;285:653-669.
16. Infliximab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: Updated May 21, 2018.
17. Micromedex DrugDex Compendium®. 2023. Infliximab.

18. Farraye F, Melmed G, Lichtenstein G, Kane S. ACG clinical guideline: Preventive care in inflammatory bowel disease. *Am J of Gastro.* 2017;112(2):241-258.
19. Feuerstein J, Ho E, Shmidt E, et al. AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. *Gastroenterology.* 2021;160(7):2496-2508.
20. Ringold S, Angeles-Han S, Beukelman T, et al. 2019 American college of rheumatology/arthritis foundation guideline for the treatment of juvenile idiopathic arthritis: Therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. *Arthritis Rheumatol.* 2019;71(6):846-863.
21. Singh J, Guyatt G, Ogdie A, et al. 2018 American college of rheumatology/national psoriasis foundation guideline for the treatment of psoriatic arthritis. *Arthritis Care Res.* 2019;71(1):2-29.
22. National Comprehensive Cancer Network (NCCN). Drugs and Biologics Compendium. 2023. Infliximab.
23. Micromedex DrugDex Compendium®.2023. Infliximab-abda.
24. Micromedex DrugDex Compendium®.2023. Infliximab-axxq.
25. Micromedex DrugDex Compendium®.2023. Infliximab-dyyb.
26. Sakkat A, Cox G, Khalidi N, et al. Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis. *Respiratory Research.* 2022;23:54.